Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat.
Breathing low oxygen levels for several weeks produces progressive pulmonary artery hypertension and smooth muscle hypertrophy and hyperplasia in many species. Because nitric oxide (NO) is an important regulator of pulmonary vascular tone, we examined whether the continuous inhalation of low levels of NO gas would attenuate pulmonary arterial structural changes in hypoxic rat pups. Nine-day-old rat pups and their mothers continuously breathed at FIO2 0.21 or 0.10 with or without adding 20 ppm (by volume) NO for 2 weeks. Lung tissue was obtained for vascular morphometric analysis, and the hearts were dissected to measure right ventricular weight and levels of mRNA encoding rat atrial natriuretic factor (rANF). In addition, femur and skull length were radiographically determined. Breathing at FIO2 0.10 for 14 days increased pulmonary arterial wall thickness and the proportion of muscular arteries in the lung periphery. Right ventricular weight and right ventricular rANF gene expression increased, whereas body weight and skeletal growth were reduced (all P < .05). Continuous inhalation of 20 ppm NO at FIO2 0.10 for 2 weeks decreased hypoxic pulmonary vascular structural changes and somatic growth retardation and prevented the increase of right ventricular weight and right ventricular rANF mRNA levels. These observations suggest that chronically breathing NO attenuates pulmonary vascular smooth muscle hypertrophy and/or hyperplasia and extension into distal arterial walls, right ventricular hypertrophy, and growth retardation of newborns breathing at a low oxygen level.
Roberts
J D
JD
Department of Anaesthesia, Harvard Medical School, Massachusetts General Hospital, Boston 02114.
Roberts
C T
CT
Jones
R C
RC
Zapol
W M
WM
Bloch
K D
KD
D000280:Administration, Inhalation; D000818:Animals; D000831:Animals, Newborn / Q000254:growth & development*; D009320:Atrial Natriuretic Factor / Q000235:genetics; D001769:Blood / Q000187:drug effects; D005260:Female; D006130:Growth Disorders / Q000473:pathology*; D006352:Heart Ventricles; D017380:Hypertrophy, Right Ventricular / Q000209:etiology / Q000473:pathology*; D000860:Hypoxia / Q000150:complications / Q000473:pathology*; D008297:Male; D009206:Myocardium / Q000473:pathology; D009569:Nitric Oxide / Q000008:administration & dosage* / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D011651:Pulmonary Artery / Q000187:drug effects* / Q000473:pathology; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins
D012333:RNA, Messenger; D011994:Recombinant Proteins; D009569:Nitric Oxide; D009320:Atrial Natriuretic Factor